Darwin Ling is an entrepreneur, technologist, angel investor, and advisor for various startups. Most recently, Darwin served as the CTO and co-founder of SmarterMe, which aims to improve sales productivity by bringing AI / Intelligence to the flow of work. Counting enterprise customers such as Danaher (Fortune 500 medical device), Home Depot and GE, SmarterMe was acquired in 2017. Due to his entrepreneurial success, Darwin was featured as one of  Purdue Tech Titans

Prior to that, Darwin was a founding member of Skyfire (mobile browser, acquired by Opera), Jaxtr (social calling, acquired by Hotmail founder), Dazel (enterprise printing, acquired by HP).

Darwin also serves as an advisory board member for Alpha Info, an industry 4.0 company that uses advanced technologies such as Big Data Analytics, IoT, Cloud Computing, AOI (Automatic Optical Inspection), Machine Vision to streamline the automation for some of the leading semiconductor foundries in China/Taiwan.

Darwin received his MBA (Honors) from the University of Chicago Booth School of Business. He also holds a BS/MS in Computer Science and Mathematics from Purdue University with distinction. 

As a neuroscientist, entrepreneur and an inventor, Milad has a unique blend of experiences in academia, research, startups and large organizations that span across fields in artificial intelligence(AI), nanotechnology, enterprise software, life sciences and healthcare. Milad is the recently appointed Visiting Scholar in Healthcare Engineering at the Regenstrief Center.

Prior to Good AI Capital, he was a leader in Accenture’s Global R&D and Incubation Hub where he helped launch new global products and innovative services for some of the leading pharmaceutical companies using emerging technologies such as AI, Advanced Analytics, Blockchain, IoT and design thinking methodologies.

As one of the youngest researchers in the US inducted into the Sigma Xi Research Honor Society, Milad has multiple publications from his research at Purdue’s Birck Nanotechnology Center and Interfacial Multiphysics Laboratory. Milad also co-founded and was the COO of Symmetry Therapeutics, an early-stage biotech company that raised money to develop their patented drug platform to treat metabolic diseases.  He was also part of the founding team at Cellaflora, a software startup that was later acquired. 

As a National Science Foundation Scholar and Macklin Fellow at Hopkins Medicine, Milad graduated Phi Beta Kappa with his BS (distinction) in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his Masters of Science in Immunology & Public Health at Maynooth University in Ireland.